These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 27825140)

  • 1. An early biomarker and potential therapeutic target of RUNX 3 hypermethylation in breast cancer, a system review and meta-analysis.
    Lu DG; Ma YM; Zhu AJ; Han YW
    Oncotarget; 2017 Mar; 8(13):22166-22174. PubMed ID: 27825140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathological significance and potential drug target of RUNX3 in breast cancer.
    Yu YY; Chen C; Kong FF; Zhang W
    Drug Des Devel Ther; 2014; 8():2423-30. PubMed ID: 25525332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinicopathological significance of RUNX3 hypermethylation and mRNA expression in human breast cancer, a meta-analysis.
    Song XY; Li BY; Zhou EX; Wu FX
    Onco Targets Ther; 2016; 9():5339-47. PubMed ID: 27616890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinicopathological significance and drug target potential of FHIT in breast cancer, a meta-analysis and literature review.
    Su Y; Wang X; Li J; Xu J; Xu L
    Drug Des Devel Ther; 2015; 9():5439-45. PubMed ID: 26491255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological significance and potential drug target of CDH1 in breast cancer: a meta-analysis and literature review.
    Huang R; Ding P; Yang F
    Drug Des Devel Ther; 2015; 9():5277-85. PubMed ID: 26425077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RUNX3 inactivation by frequent promoter hypermethylation and protein mislocalization constitute an early event in breast cancer progression.
    Subramaniam MM; Chan JY; Soong R; Ito K; Ito Y; Yeoh KG; Salto-Tellez M; Putti TC
    Breast Cancer Res Treat; 2009 Jan; 113(1):113-21. PubMed ID: 18256927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological significance and potential drug target of RUNX3 in non-small cell lung cancer: a meta-analysis.
    Xu L; Lan H; Su Y; Li J; Wan J
    Drug Des Devel Ther; 2015; 9():2855-65. PubMed ID: 26082616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of RUNX3 gene, methylation status and clinicopathological significance in breast cancer and breast cancer cell lines.
    Jiang Y; Tong D; Lou G; Zhang Y; Geng J
    Pathobiology; 2008; 75(4):244-51. PubMed ID: 18580070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The association of PTEN hypermethylation and breast cancer: a meta-analysis.
    Luo S; Chen J; Mo X
    Onco Targets Ther; 2016; 9():5643-50. PubMed ID: 27672335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathological significance of RUNX3 gene hypermethylation in hepatocellular carcinoma.
    Yang Y; Ye Z; Zou Z; Xiao G; Luo G; Yang H
    Tumour Biol; 2014 Oct; 35(10):10333-40. PubMed ID: 25037468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RUNX3 Epigenetic Inactivation Is Associated With Estrogen Receptor Positive Breast Cancer.
    Liu H; Yan Z; Yin Q; Cao K; Wei Y; Rodriguez-Canales J; Ma D; Wu Y
    J Histochem Cytochem; 2018 Oct; 66(10):709-721. PubMed ID: 30133331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Correlation between the methylation status of Runx3 gene and positive expression of estrogen receptor in breast cancer].
    Yan Z; Gao S; Wu X; Liu H
    Zhonghua Bing Li Xue Za Zhi; 2015 Apr; 44(4):240-4. PubMed ID: 25975905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of promoter methylation of RUNX3 gene with the development of esophageal cancer: a meta analysis.
    Wang Y; Qin X; Wu J; Qi B; Tao Y; Wang W; Liu F; Li H; Zhao B
    PLoS One; 2014; 9(9):e107598. PubMed ID: 25229459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer.
    Lau QC; Raja E; Salto-Tellez M; Liu Q; Ito K; Inoue M; Putti TC; Loh M; Ko TK; Huang C; Bhalla KN; Zhu T; Ito Y; Sukumar S
    Cancer Res; 2006 Jul; 66(13):6512-20. PubMed ID: 16818622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RUNX3 Promoter Methylation Is Associated with Hepatocellular Carcinoma Risk: A Meta-Analysis.
    Zhang X; He H; Zhang X; Guo W; Wang Y
    Cancer Invest; 2015 Apr; 33(4):121-5. PubMed ID: 25664646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A systematic review and meta-analysis of runt-related transcription factor 3 gene promoter hypermethylation and risk of gastric cancer.
    Xia Y; Zhang M; Zhang X; Liu X
    J Cancer Res Ther; 2014 Dec; 10 Suppl():310-3. PubMed ID: 25693942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypermethylation downregulates Runx3 gene expression and its restoration suppresses gastric epithelial cell growth by inducing p27 and caspase3 in human gastric cancer.
    Chen W; Gao N; Shen Y; Cen JN
    J Gastroenterol Hepatol; 2010 Apr; 25(4):823-31. PubMed ID: 20492341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The association between runt-related transcription factor 3 gene promoter methylation and gastric cancer: A meta-analysis.
    Liu X; Wang L; Guo Y
    J Cancer Res Ther; 2016 Oct; 12(Supplement):50-53. PubMed ID: 27721253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RUNX3 methylation as a predictor for disease progression in patients with non-muscle-invasive bladder cancer.
    Yan C; Kim YW; Ha YS; Kim IY; Kim YJ; Yun SJ; Moon SK; Bae SC; Kim WJ
    J Surg Oncol; 2012 Mar; 105(4):425-30. PubMed ID: 22311819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Relationship between hypermethylation of Runx3 gene and the development and metastasis of laryngeal carcinoma].
    Tang J; Bai W; Ji W; Gao H; Liu J
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2010 Sep; 24(18):834-7. PubMed ID: 21254652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.